Pfizer says once-a-month weight-loss drug works as it forecasts profit decline
Pfizer on Tuesday hailed a study of a weight-loss-drug candidate while forecasting a profit decline due to the impact of the Trump administration’s policies on pricing and tariffs.
Related Posts
Tower Semiconductor beats quarterly profit estimates on AI-driven chip demand
Tower Semiconductor beats quarterly profit estimates on AI-driven chip demand
Are tips taxable? Here’s how the new ‘no tax on tips’ deduction works.
For millions of service workers, the promise of “no tax on tips” sounds like a straight boost to your paycheck. But the reality...
Bitcoin mining profit crisis hits as difficulty to drop by 14% this weekend while block time spikes to 20 minutes
While price action has always been volatile and, arguably, exciting, the Bitcoin network itself is built to feel boring. Ten minut...
Novo Nordisk CEO tells investors to expect weight-loss drug pricing to go down before it comes back up
Recently-appointed CEO Mike Doustdar has repeatedly reset expectations since his arrival. Pricing and regulatory pressure is fierce an...
Nintendo posts quarterly profit rise, sees no major hit from chip price spike
Nintendo posts quarterly profit rise, sees no major hit from chip price spike